Coverage Policies

Important! Please note:

Current policies effective through April 30, 2024.

Take me to policies effective May 1, 2024.

Use the index below to search for coverage information on specific medical conditions.

High-Tech Imaging: High-Tech Imaging services are administered by Evolent. For coverage information and authorizations, click here.

Medical Providers: Payment for care or services is based on eligibility, medical necessity and available benefits at time of service and is subject to all contractual exclusions and limitations, including pre-existing conditions if applicable.

Future eligibility cannot be guaranteed and should be rechecked at time of service. Verify benefits by signing into My Account or calling Customer Service at 800.235.7111 or 501.228.7111.

QualChoice follows care guidelines published by MCG Health.

Clinical Practice Guidelines for Providers (PDF)

QualChoice reserves the right to alter, amend, change or supplement medical policies as needed. QualChoice reviews and authorizes services and substances. CPT and HCPCS codes are listed as a convenience and any absent, new or changed codes do not alter the intent of the policy.

INDEX:



Effective Date: 09/01/2014	Title: Intravenous Iron Products
Revision Date: 08/05/2022	Document: BI452:00
CPT Code(s): C9441, J1439, J1750, J1756, J2916, Q0138, Q0139, Q9970
Public Statement
*Effective Date:* a) This policy will apply to all services performed on or after the above revision date which will become the new effective date. b) For all services referred to in this policy that were performed before the revision date, contact customer service for the rules that would apply. 1) Intravenous iron products are covered to treat iron deficiency anemia. 2) Covered products include Venofer, Feraheme, Ferrlecit, and Iron Dextran. 3) Injectafer is not covered.
Medical Statement
Some intravenous iron products are covered for the treatment of iron deficiency anemia, including Venofer, Feraheme, Ferrlecit, and Iron Dextran. Injectafer is not covered. Codes Used In This BI: Covered J1756 – Injection, Iron Sucrose, 1mg Q0138 – Injection, Ferumoxytol, 1gm (for non-ESRD use) Q0139 – Injection, Ferumoxytol, 1mg (for ESRD on dialysis) J2916 – Injection, Sodium Ferric Fluconate complex in sucrose injection, 12.5mg J1750 – Injection, Iron Dextran, 50mg Not covered C9441 - Injection, Ferric Carboxymaltose, 1mg Q9970 - Injection, Ferric Carboxymaltose, 1mg J1439 – Injection, Ferric Carboxymaltose, 1mg
Reference
1) Venofer Product Information. American Regent, Inc. June 2011. 2) Feraheme Product Information. AMAG Pharmaceuticals, Inc. 2014. 3) Ferrlecit Product Information. Sanofi-Aventis. 2011. 4) Infed Product Information. Watson Pharma, Inc. September 2009. 5) Auerbach M, Ballard H. Clinical Use of Intravenous: Administration, Efficacy, and Safety. Hematology Am Soc Hematol Educ Program 2010;2010:338-347
Application to Products
This policy applies to all health plans administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet. Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) for those plans insured by QualChoice. In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC, the SPD or EOC, as applicable, will prevail. State and federal mandates will be followed as they apply.
Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.

This policy has recently been updated. Please use the index above or enter policy title in search bar for the latest version.